Metformina + Vildagliptina Tolife

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Tolife, is a biguanide presented as an oral tablet for oral use. Together with Vildagliptin, a DPP‑4 inhibitor, the combination is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower blood glucose by reducing hepatic glucose output and enhancing insulin secretion.

GNH USA supplies Metformina + Vildagliptina Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across all markets.

Metformina + Vildagliptina Tolife combines a biguanide and a DPP‑4 inhibitor to improve glycemic control in type 2 diabetes.

- Type 2 diabetes mellitus (initial therapy): used as first‑line oral treatment to lower fasting and post‑prandial glucose. - Type 2 diabetes mellitus (add‑on therapy): added when metformin alone does not achieve glycemic targets. - Type 2 diabetes mellitus (combination therapy): employed together with other oral agents or insulin to achieve tighter control.

The most frequently reported reactions relate to the gastrointestinal tract and mild metabolic changes.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Dizziness - Mild hypoglycemia (especially with sulfonylureas or insulin)

Serious or Rare Side Effects: - Lactic acidosis - Acute pancreatitis - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Renal impairment - Severe hypoglycemia

Careful assessment and monitoring are required to minimise risks associated with the combination therapy.

- Renal function: assess eGFR before initiating and monitor periodically. - Hepatic impairment: use with caution; monitor liver enzymes. - Lactic acidosis risk: avoid in patients with significant renal or hepatic disease. - Hypoglycemia risk: monitor closely when combined with insulin or sulfonylureas. - Pregnancy and lactation: evaluate risk‑benefit; generally not recommended. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformina + Vildagliptina Tolife may interact with several drug classes, requiring avoidance or close monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis. - Cimetidine: can raise metformin plasma concentrations. - Alcohol abuse: heightened risk of lactic acidosis. - Strong CYP2C9 inhibitors (e.g., fluconazole): may affect vildagliptin metabolism.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function. - Diuretics: may alter renal clearance of metformin. - Beta‑blockers: can mask hypoglycemia symptoms. - Thyroid hormones: may influence glucose metabolism. - Rifampicin: may reduce vildagliptin plasma levels.